ViewMind Applauded by Frost & Sullivan for Its One-of-a-kind Digital Biomarker Technology for Neurocognitive Disorders
Related Posts
Scarlett Chen from Verge HealthTech Fund joins ViewMind’s board of directors
ViewMind today announced Scarlett Sijia Chen, Managing Partner of Verge HealthTech Fund, has been elected to ViewMind’s board of directors. Scarlett brings decades of experience…
Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer’s disease
Oculomotor behaviors linked to cognitive performance revealed neurocognitive features of Alzheimer’s disease (AD) that can enhance the accuracy of its assessment and diagnosis
ViewMind: Most Innovative Digital Health A.I. Company – Europe & Leading Experts in Neurocognitive Digital Biomarkers
ViewMind: Most Innovative Digital Health A.I. Company – Europe & Leading Experts in Neurocognitive Digital Biomarkers Homepage >> Press Releases >> ViewMind: Most Innovative Digital Health A.I. Company
